GRIP

GRIP Molecular Technologies is pioneering the next generation of CRISPR-based diagnostics with a molecular test platform for lateral flow assays. Powered by a CRISPR protease engine, GRIP's diagnostic platform detects pathogen RNA and amplifies signal in minutes, providing accurate results without nucleic acid amplification. The technology operates at room temperature, is pathogen and sample agnostic, and uses stable proteins as reporter substrates to avoid false positives from nucleases. The platform supports multiple readout methods including lateral flow assays, electrochemical tests, and colorimetric assays, with plug-and-play manufacturing that integrates into proven immunoassay pipelines. GRIP targets the over $2 billion per year global market for point-of-care diagnostics for STIs, UTIs, and upper respiratory infections. Founded in 2019, headquartered in Saint Paul, United States, The company has raised $14.7M at the Series A stage, backed by investors including EvoNexus, gBETA Medtech, JLABS..